Top

16-04-2024 | Metamizole | Original Article

Neuroendocrine modulation by metamizole and indomethacin: investigating the impact on neuronal markers and GnRH release

Authors: Erkan Maytalman, Dilara Nemutlu Samur

Published in: Endocrine

Abstract

Purpose

Some evidence that non-steroidal anti-inflammatory drugs have neuroprotective effects indicates their potential for use in a new field. However, their effects on hormone secretion have yet to be adequately discovered. Therefore, we aimed to evaluate the effects of metamizole and indomethacin on neuronal markers as well as the GnRH expression in the GT1-7 cell line.

Methods

The effects of these drugs on proliferation were evaluated by MTT analysis. The effect of 10–50–250 µM concentrations of the drugs also on the expression of neuronal factors and markers, including NGF, nestin and βIII Tubulin, and additionally GnRH, was determined by the RT-qPCR method.

Results

NGF and nestin mRNA expressions were increased in all concentrations of both metamizole and indomethacin. No changes were detected in βIII Tubulin. While metamizole showed an increase in GnRH mRNA expression, there was no change at 10 and 50 µM concentrations of indomethacin, but a remarkable decrease was observed at 250 µM concentrations.

Conclusions

The results of our study showing an increase in the expression of neuronal factors reveal that metamizole and indomethacin may have possible neuroprotective effects. Moreover, the effects on the GnRH expression appear to be different. Animal models are required to confirm these effects of NSAIDs on neurons.

X. Chen, W. Pan, The Treatment Strategies for Neurodegenerative Diseases by Integrative Medicine. Integr. Med. Int. 1(4), 223–225 (2015). https://doi.org/10.1159/000381546CrossRef

T.J. Moore, H. Abrahamse, Neuronal Differentiation of Adipose-Derived Stem Cells: Progress So Far. Int. J. Photoenergy. 1–8 (2014). https://doi.org/10.1155/2014/827540

M.A. Ajmone-Cat, A. Bernardo, A. Greco, L. Minghetti, Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions. Pharmceuticals 3(6), 1949–1965 (2010). https://doi.org/10.3390/ph3061949CrossRef

M. Terzi, G. Altun, S. Şen, A. Kocaman, A.A. Kaplan, K.K. Yurt, S. Kaplan, The use of non-steroidal anti-inflammatory drugs in neurological diseases. J. Chem. Neuroanat. 87, 12–24 (2018). https://doi.org/10.1016/j.jchemneu.2017.03.003CrossRefPubMed

K.P. Townsend, D. Praticò, Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 19(12), 1592–1601 (2005). https://doi.org/10.1096/fj.04-3620revCrossRefPubMed

B.A. in t’ Veld, A. Ruitenberg, A. Hofman, L.J. Launer, C.M. van Duijn, T. Stijnen, M.M. Breteler, B.H. Stricker, Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N. Engl. J. Med. 345(21), 1515–1521 (2001). https://doi.org/10.1056/NEJMoa010178CrossRefPubMed

K.D. Rainsford, Safety and Efficacy of Non-prescription, Over-the-counter (OTC) Ibuprofen. In Ibuprofen: Discovery, Development and Therapeutics. John Wiley. 313–345, (2015). https://doi.org/10.1002/9781118743614.ch7.

P.H. Ashjian, A.S. Elbarbary, B. Edmonds, D. DeUgarte, M. Zhu, P.A. Zuk, H.P. Lorenz, P. Benhaim, M.H. Hedrick, In vitro differentiation of human processed lipoaspirate cells into early neural progenitors. Plast. Reconstr. Surg. 111(6), 1922–1931 (2003). https://doi.org/10.1097/01.PRS.0000055043.62589.05CrossRefPubMed

J.A. McGuiness, R.B. Scheinert, A. Asokan, V.C. Stadler, C.S. Lee, A. Rani, A. Kumar, T.C. Foster, B.K. Ormerod, Indomethacin Increases Neurogenesis across Age Groups and Improves Delayed Probe Trial Difference Scores in Middle-Aged Rats. Front. Aging Neurosci. 9, 280 (2017). https://doi.org/10.3389/fnagi.2017.00280CrossRefPubMedPubMedCentral

10.

E.G. Hain, M. Sparenberg, J. Rasińska, C. Klein, L. Akyüz, B. Steiner, Indomethacin promotes survival of new neurons in the adult murine hippocampus accompanied by anti-inflammatory effects following MPTP-induced dopamine depletion. J. Neuroinflammation 15(1), 162 (2018). https://doi.org/10.1186/s12974-018-1179-4CrossRefPubMedPubMedCentral

11.

Y. Zhang, X. Wang, S.V. Baranov, S. Zhu, Z. Huang, W. Fellows-Mayle, J. Jiang, A.L. Day, B.S. Kristal, R.M. Friedlander, Dipyrone inhibits neuronal cell death and diminishes hypoxic/ischemic brain injury. Neurosurgery 69(4), 942–956 (2011). https://doi.org/10.1227/NEU.0b013e318222afb2CrossRefPubMed

12.

E.F. Collares, L.E.A. Troncon, Effects of dipyrone on the digestive tract. Braz. J. Med. Biol. Res. 52(2), e8103 (2019). https://doi.org/10.1590/1414-431X20188103CrossRefPubMedPubMedCentral

13.

M. Fukuchi, Identifying inducers of BDNF gene expression from pharmacologically validated compounds; antipyretic drug dipyrone increases BDNF mRNA in neurons. Biochem. Biophys. Res. Commun. 524(4), 957–962 (2020). https://doi.org/10.1016/j.bbrc.2020.02.019CrossRefPubMed

14.

I. Nikolova, L. Marinov, A. Georgieva, R. Toshkova, M. Malchev, Y. Voynikov, I. Kostadinova, Metamizole (dipyrone) – cytotoxic and antiproliferative effects on HeLa, HT-29 and MCF-7 cancer cell lines. Biotechnol. Biotechnological Equip. 32(5), 1327–1337 (2018). https://doi.org/10.1080/13102818.2018.1511382CrossRef

15.

E. Maytalman, D.N. Samur, O.C. Gunizi, I. Kozanoglu, The effects of metamizole on hematopoietic progenitor cells: Suppression of hematopoiesis stimulation in vitro. Bratisl. Lek. Listy 124(4), 320–329 (2023). https://doi.org/10.4149/BLL_2023_049CrossRefPubMed

16.

D. Mizuno, K. Konoha-Mizuno, M. Mori, K. Yamazaki, T. Haneda, H. Koyama, M. Kawahara, An In Vitro System Comprising Immortalized Hypothalamic Neuronal Cells (GT1-7 Cells) for Evaluation of the Neuroendocrine Effects of Essential Oils. Evid. Based Complement Altern. Med 2015, 343942 (2015). https://doi.org/10.1155/2015/343942CrossRef

17.

L. Casati, S. Ciceri, R. Maggi, D. Bottai, Physiological and pharmacological overview of the gonadotropin releasing hormone. Biochem. Pharm. 212, 115553 (2023). https://doi.org/10.1016/j.bcp.2023.115553CrossRefPubMed

18.

B. Connor, M. Dragunow, The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Rev. 27(1), 1–39 (1998). https://doi.org/10.1016/s0165-0173(98)00004-6CrossRefPubMed

19.

F. Martorana, D. Gaglio, M.R. Bianco, F. Aprea, A. Virtuoso, M. Bonanomi, L. Alberghina, M. Papa, A.M. Colangelo, Differentiation by nerve growth factor (NGF) involves crosstalk mechanisms between energy homeostasis and mitochondrial remodeling. Cell Death Dis. 9(3), 391 (2018). https://doi.org/10.1038/s41419-018-0429-9CrossRefPubMedPubMedCentral

20.

J. Biane, J.M. Conner, M.H. Tuszynski, Nerve growth factor is primarily produced by GABAergic neurons of the adult rat cortex. Front. Cell Neurosci. 8, 220 (2014). https://doi.org/10.3389/fncel.2014.00220CrossRefPubMedPubMedCentral

21.

J. Luo, Y. Yang, T. Zhang, Z. Su, D. Yu, Q. Lin, H. Chen, Q. Zhang, Q. Xiang, W. Xue, R. Ge, Y. Huang, Nasal delivery of nerve growth factor rescue hypogonadism by up-regulating GnRH and testosterone in aging male mice. EBioMedicine 35, 295–306 (2018). https://doi.org/10.1016/j.ebiom.2018.08.021CrossRefPubMedPubMedCentral

22.

M.H. Ratto, L. Paiva, R. Carrasco, M.E. Silva, C. Ulloa-Leal, V.F. Ratto, J. Goicochea, Review: Unveiling the effect of beta-nerve growth factor on the reproductive function in llamas and cows. Animal 17(Suppl 1), 100754 (2023). https://doi.org/10.1016/j.animal.2023.100754CrossRefPubMed

23.

F. Pimpinelli, E. Redaelli, R. Restano-Cassulini, G. Curia, P. Giacobini, A. Cariboni, E. Wanke, G.P. Bondiolotti, F. Piva, R. Maggi, Depolarization differentially affects the secretory and migratory properties of two cell lines of immortalized luteinizing hormone-releasing hormone (LHRH) neurons. Eur. J. Neurosci. 18(6), 1410–1418 (2003). https://doi.org/10.1046/j.1460-9568.2003.02866.xCrossRefPubMed

24.

S. Suzuki, J. Namiki, S. Shibata, Y. Mastuzaki, H. Okano, The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J. Histochem. Cytochem. 58(8), 721–730 (2010). https://doi.org/10.1369/jhc.2010.955609CrossRefPubMedPubMedCentral

25.

M.L. Hendrickson, A.J. Rao, O.N. Demerdash, R.E. Kalil, Expression of nestin by neural cells in the adult rat and human brain. PLoS One 6(4), e18535 (2011). https://doi.org/10.1371/journal.pone.0018535CrossRefPubMedPubMedCentral

26.

R.G. Romanelli, T. Barni, M. Maggi, M. Luconi, P. Failli, A. Pezzatini, E. Pelo, F. Torricelli, C. Crescioli, P. Ferruzzi, R. Salerno, M. Marini, C.M. Rotella, G.B. Vannelli, Expression and function of gonadotropin-releasing hormone (GnRH) receptor in human olfactory GnRH-secreting neurons: an autocrine GnRH loop underlies neuronal migration. J. Biol. Chem. 279(1), 117–126 (2004). https://doi.org/10.1074/jbc.M307955200CrossRefPubMed

27.

E.M. Jouhilahti, S. Peltonen, J. Peltonen, Class III beta-tubulin is a component of the mitotic spindle in multiple cell types. J. Histochem. Cytochem. 56(12), 1113–1119 (2008). https://doi.org/10.1369/jhc.2008.952002CrossRefPubMedPubMedCentral

28.

E. Dráberová, L. Del Valle, J. Gordon, V. Marková, B. Smejkalová, L. Bertrand, J.P. de Chadarévian, D.P. Agamanolis, A. Legido, K. Khalili, P. Dráber, C.D. Katsetos, Class III beta-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. J. Neuropathol. Exp. Neurol. 67(4), 341–354 (2008). https://doi.org/10.1097/NEN.0b013e31816a686dCrossRefPubMed

29.

S.A. Malone, G.E. Papadakis, A. Messina, N.E.H. Mimouni, S. Trova, M. Imbernon, C. Allet, I. Cimino, J. Acierno, D. Cassatella, C. Xu, R. Quinton, G. Szinnai, P. Pigny, L. Alonso-Cotchico, L. Masgrau, J.D. Maréchal, V. Prevot, N. Pitteloud, P. Giacobini, Defective AMH signaling disrupts GnRH neuron development and function and contributes to hypogonadotropic hypogonadism. Elife 8, e47198 (2019). https://doi.org/10.7554/eLife.47198CrossRefPubMedPubMedCentral

30.

P.I. Lorenzo, C. Ménard, F.D. Miller, J. Bernal, Thyroid hormone-dependent regulation of Talpha1 alpha-tubulin during brain development. Mol. Cell Neurosci. 19(3), 333–343 (2002). https://doi.org/10.1006/mcne.2001.1087CrossRefPubMed

31.

P.R. Kramer, S. Wray, Midline nasal tissue influences nestin expression in nasal-placode-derived luteinizing hormone-releasing hormone neurons during development. Dev. Biol. 227(2), 343–357 (2000). https://doi.org/10.1006/dbio.2000.9896CrossRefPubMed

32.

R. Tsutsumi, N.J. Webster, GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr. J. 56(6), 729–737 (2009). https://doi.org/10.1507/endocrj.k09e-185CrossRefPubMedPubMedCentral

33.

N. Wickramasuriya, R. Hawkins, C. Atwood, T. Butler, The roles of GnRH in the human central nervous system. Horm. Behav. 145, 105230 (2022). https://doi.org/10.1016/j.yhbeh.2022.105230CrossRefPubMedPubMedCentral

34.

E. De Luna-Bertos, J. Ramos-Torrecillas, F.J. Manzano-Moreno, O. García-Martínez, C. Ruiz, Effects on growth of human osteoblast-like cells of three nonsteroidal anti-inflammatory drugs: metamizole, dexketoprofen, and ketorolac. Biol. Res. Nurs. 17(1), 62–67 (2015). https://doi.org/10.1177/1099800414527155CrossRefPubMed

35.

E. De Luna-Bertos, J. Ramos-Torrecillas, O. García-Martínez, A. Guildford, M. Santin, C. Ruiz, Therapeutic doses of nonsteroidal anti-inflammatory drugs inhibit osteosarcoma MG-63 osteoblast-like cells maturation, viability, and biomineralization potential. Sci. World J. 2013, 809891 (2013). https://doi.org/10.1155/2013/809891CrossRef

36.

C. Pompeia, M.F. Boaventura, R. Curi, Antiapoptotic effect of dipyrone on HL-60, Jurkat and Raji cell lines submitted to UV irradiation, arachidonic acid and cycloheximide treatments. Int Immunopharmacol. 1(12), 2173–2182 (2001). https://doi.org/10.1016/s1567-5769(01)00144-8CrossRefPubMed

37.

A.C. Bundscherer, M. Malsy, M.A. Gruber, B.M. Graf, B. Sinner, Acetaminophen and Metamizole Induce Apoptosis in HT 29 and SW 480 Colon Carcinoma Cell Lines In Vitro. Anticancer Res. 38(2), 745–751 (2018). https://doi.org/10.21873/anticanres.12280CrossRefPubMed

38.

J. Shao, G. Feng, Selective killing effect of oxytetracycline, propafenone and metamizole on A549 or Hela cells. Chin. J. Cancer Res. 25(6), 662–670 (2013). https://doi.org/10.3978/j.issn.1000-9604.2013.11.05CrossRefPubMedPubMedCentral

39.

M. Malsy, B. Graf, A. Bundscherer, Effects of metamizole, MAA, and paracetamol on proliferation, apoptosis, and necrosis in the pancreatic cancer cell lines PaTu 8988 t and Panc-1. BMC Pharm. Toxicol. 18(1), 77 (2017). https://doi.org/10.1186/s40360-017-0185-yCrossRef

40.

A. Yavuz, G. Oner, M. Tas, M. Sonmezer, The impact of indomethacin on the number of oocytes retrieved and IVF outcomes in patients with poor ovarian response. Eur. J. Obstet. Gynecol. Reprod. Biol. 264, 266–270 (2021). https://doi.org/10.1016/j.ejogrb.2021.07.035CrossRefPubMed

41.

L. Díaz-Rodríguez, O. García-Martínez, M.A. Morales, L. Rodríguez-Pérez, B. Rubio-Ruiz, C. Ruiz, Effects of indomethacin, nimesulide, and diclofenac on human MG-63 osteosarcoma cell line. Biol. Res. Nurs. 14(1), 98–107 (2012). https://doi.org/10.1177/1099800411398933CrossRefPubMed

42.

S. Mirshahidi, R. de Necochea-Campion, A. Moretta, N.L. Williams, M.E. Reeves, S. Otoukesh, H.R. Mirshahidi, S. Khosrowpour, P. Duerksen-Hughes, L.M. Zuckerman, Inhibitory Effects of Indomethacin in Human MNNG/HOS Osteosarcoma Cell Line In Vitro. Cancer Invest. 38(1), 23–36 (2020). https://doi.org/10.1080/07357907.2019.1698592CrossRefPubMed

43.

G. Zhang, C. Tu, G. Zhang, G. Zhou, W. Zheng, Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk. Res. 24(5), 385–392 (2000). https://doi.org/10.1016/s0145-2126(99)00198-8CrossRefPubMed

44.

M. Yorifuji, Y. Sawaji, K. Endo, T. Kosaka, K. Yamamoto, Limited efficacy of COX-2 inhibitors on nerve growth factor and metalloproteinases expressions in human synovial fibroblasts. J. Orthop. Sci. 21(3), 381–388 (2016). https://doi.org/10.1016/j.jos.2016.01.004CrossRefPubMed

45.

B.D. Hoehn, T.D. Palmer, G.K. Steinberg, Neurogenesis in rats after focal cerebral ischemia is enhanced by indomethacin. Stroke 36(12), 2718–2724 (2005). https://doi.org/10.1161/01.STR.0000190020.30282.ccCrossRefPubMed

46.

S. Salian-Mehta, M. Xu, T.A. McKinsey, S. Tobet, M.E. Wierman, Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement. J. Biol. Chem. 290(22), 14045–14056 (2015). https://doi.org/10.1074/jbc.M115.640482CrossRefPubMedPubMedCentral

47.

S.R. Ojeda, P.G. Harms, S.M. McCann, Effect of inhibitors of prostaglandin synthesis on gonadotropin release in the rat. Endocrinology 97(4), 843–854 (1975). https://doi.org/10.1210/endo-97-4-843CrossRefPubMed

48.

L.G. Erkan, B. Altinbas, G. Guvenc, S. Alcay, M.B. Toker, B. Ustuner, D. Udum Kucuksen, M. Yalcin, Brain thromboxane A2 via arachidonic acid cascade induces the hypothalamic-pituitary-gonadal axis activation in rats. Auton. Neurosci. 189, 50–55 (2015). https://doi.org/10.1016/j.autneu.2015.02.005CrossRefPubMed

49.

S.R. Ojeda, H.F. Urbanski, K.H. Katz, M.E. Costa, P.M. Conn, Activation of two different but complementary biochemical pathways stimulates release of hypothalamic luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 83(13), 4932–4936 (1986). https://doi.org/10.1073/pnas.83.13.4932CrossRefPubMedPubMedCentral

50.

Z. Naor, K.J. Catt, Mechanism of action of gonadotropin-releasing hormone. Involvement of phospholipid turnover in luteinizing hormone release. J. Biol. Chem. 256(5), 2226–2229 (1981)CrossRefPubMed

51.

J. Clasadonte, P. Poulain, N.K. Hanchate, G. Corfas, S.R. Ojeda, V. Prevot, Prostaglandin E2 release from astrocytes triggers gonadotropin-releasing hormone (GnRH) neuron firing via EP2 receptor activation. Proc. Natl. Acad. Sci. USA 108(38), 16104–16109 (2011). https://doi.org/10.1073/pnas.1107533108CrossRefPubMedPubMedCentral

52.

Z. Naor, H.N. Jabbour, M. Naidich, A.J. Pawson, K. Morgan, S. Battersby, M.R. Millar, P. Brown, R.P. Millar, Reciprocal cross talk between gonadotropin-releasing hormone (GnRH) and prostaglandin receptors regulates GnRH receptor expression and differential gonadotropin secretion. Mol. Endocrinol. 21(2), 524–537 (2007). https://doi.org/10.1210/me.2006-0253CrossRefPubMed

53.

Y. Kagawa, B.A. Umaru, S.K. Shil, K. Hayasaka, R. Zama, Y. Kobayashi, H. Miyazaki, S. Kobayashi, C. Suzuki, Y. Katori, T. Abe, Y. Owada, Mitochondrial dysfunction in GnRH neurons impaired GnRH production. Biochem. Biophys. Res. Commun. 530(1), 329–335 (2020). https://doi.org/10.1016/j.bbrc.2020.07.090CrossRefPubMed

54.

S.C. Pierre, R. Schmidt, C. Brenneis, M. Michaelis, G. Geisslinger, K. Scholich, Inhibition of cyclooxygenases by dipyrone. Br. J. Pharm. 151(4), 494–503 (2007). https://doi.org/10.1038/sj.bjp.0707239CrossRef

55.

A. Jasiecka, T. Maślanka, J.J. Jaroszewski, Pharmacological characteristics of metamizole. Pol. J. Vet. Sci. 17(1), 207–214 (2014). https://doi.org/10.2478/pjvs-2014-0030CrossRefPubMed

56.

J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, J.R. Vane, Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90(24), 11693–11697 (1993). https://doi.org/10.1073/pnas.90.24.11693CrossRefPubMedPubMedCentral

57.

A.L. Blobaum, M.J. Uddin, A.S. Felts, B.C. Crews, C.A. Rouzer, L.J. Marnett, The 2’-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor. ACS Med. Chem. Lett. 4(5), 486–490 (2013). https://doi.org/10.1021/ml400066aCrossRefPubMedPubMedCentral

Title: Neuroendocrine modulation by metamizole and indomethacin: investigating the impact on neuronal markers and GnRH release
Authors: Erkan Maytalman
Dilara Nemutlu Samur
Publication date: 16-04-2024
Publisher: Springer US
Keywords: Metamizole
Indomethacin
Published in: Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-024-03822-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials